| July - December 2022 |
|
PERCENT (%) RESISTANCE
TO SELECTED ANTIBIOTICS BY HOSPITAL |
| |
| Acinetobacter baumannii |
| |
Amikacin (all clinical specimens) |
| |
Ciprofloxacin (all clinical specimens) |
| |
Imipenem (all clinical specimens) |
| |
Colistin (all clinical specimens) |
| Pseudomonas aeruginosa |
| |
Amikacin (all clinical specimens) |
| |
Ceftazidime (all clinical specimens) |
| |
Ciprofloxacin (all clinical specimens) |
| |
Imipenem (all clinical specimens) |
| |
Piperacillin/Tazobactam (all clinical specimens) |
| Enterobacter spp |
| |
Tobramycin (all clinical specimens) |
| |
Ceftazidime (all clinical specimens) |
| |
Ciprofloxacin (all clinical specimens) |
| |
Imipenem (all clinical specimens) |
| |
Cefepime (all clinical specimens) |
| |
Piperacillin/Tazobactam (all clinical specimens) |
| Staphylococcus aureus |
| |
MRSA (all clinical specimens) |
| Klebsiella pneumoniae |
| |
Ceftazidime (all clinical specimens) |
| |
Ciprofloxacin (all clinical specimens) |
| |
Imipenem (all clinical specimens) |
| |
Cefepime (all clinical specimens) |
| |
Tobramycin (all clinical specimens) |
|
Piperacillin/Tazobactam
(all clinical specimens) |
| Proteus mirabilis |
| |
Ceftazidime (all clinical specimens) |
| |
Ciprofloxacin (all clinical specimens) |
| |
Cefepime (all clinical specimens) |
| |
Tobramycin (all clinical specimens) |
| |
Piperacillin/Tazobactam (all clinical specimens) |
| Enterococcus spp |
| |
Gentamicin (all clinical specimens) |
| |
Vancomycin (all clinical specimens) |
| Escherichia coli |
| |
Ciprofloxacin (all clinical specimens) |
|
Piperacillin/Tazobactam
(all clinical specimens) |
|
Ceftazidime
(all clinical specimens) |
